Archive - February 2018
Aimmune Peanut Allergy Drug Meets Goal in Late-Stage Trial
Dynavax secures $175M to fuel Heplisav-B marketing, immuno-oncology trials
Gilead wins reversal of $2.54B hepatitis C patent verdict, but Merck says fight not over yet
What it costs hospitals to reverse an opioid overdose
Physicians decry consequences of consolidation
Michigan plan would move Medicaid long-term care into managed care
Former Teva generics chief Olafsson steps into CEO seat at growth-challenged Hikma
Merck CEO speaks up on Trump: Charlottesville response defied our country’s ‘basic values’